<DOC>
	<DOCNO>NCT01528111</DOCNO>
	<brief_summary>This Phase 1/2a study intend assess safety , tolerability , effect intraocular pressure two dose level two dose frequency LX7101 administer topically eyes patient diagnose primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Efficacy LX7101 Subjects With Primary Open-angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Adults â‰¥18 year age Documented diagnosis POAG OHT , eye Willing able provide write informed consent History form glaucoma either eye , POAG Subjects unwilling unable discontinue contact lens wear prior study History ocular trauma either eye &lt; 6 month prior Screening History ocular infection ocular inflammation either eye &lt; 3 month prior Screening History chronic recurrent severe inflammatory eye disease , severe ocular pathology , clinically relevant progressive retinal disease either eye Clinically relevant , severe central visual field loss , document significant progression visual field defect within 6 month prior Screening either eye Use ocular hypertensive medication ( applicable ) , either eye , washout period duration study Use glucocorticoid medication &lt; 2 week prior Screening throughout duration study Use medication substance chronic basis take stable dose least 30 day prior Screening Use nondiagnostic , topical , ophthalmic preparation , either eye , artificial tear The presence concurrent condition clinically significant laboratory finding Screening may interfere aspect safety , study conduct , interpretation result Women pregnant breast feeding Inability difficulty instill eye drop</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>